Effective treatments are still lacking for hepatocellular carcinoma or HCC, the most common type of liver cancer and second leading cause of cancer-related fatalities in Asia. Prognosis of patients with the disease has been and remains poor, with a 0.9 ratio of mortality to incidence.
A new innovative treatment approach is desperately needed to save lives of Asian patients with this deadly cancer.
Professor Daniel Tenen and his expert team of scientists at the Cancer Science Institute Singapore are designing small aptamers or very tiny pieces of RNA that will bind tightly to specific proteins associated with early development of liver cancer. These aptamers have the potential to reprogram the fate of the liver cell away from becoming cancerous and may offer the bold new treatment that patients need to save their lives. Click to learn more about this research program and its latest progress in 2020.
Can we count on your support today? When you make a generous gift to AFCR, you give HOPE to every person in Asia and around the world who is fighting liver cancer. Your generosity will lead directly to a revolutionary new approach to defeating liver cancer and creating more survivors!
Please take a moment to renew your support today. On behalf of every single man, woman, and child with liver cancer whose life you will touch through your support of AFCR, thank you again for all you can do.